Victrex (VCT) Downgraded by Morgan Stanley

Share on StockTwits

Victrex (LON:VCT) was downgraded by investment analysts at Morgan Stanley to an “underweight” rating in a research report issued on Friday, October 12th. They presently have a GBX 2,300 ($30.05) target price on the stock, down from their previous target price of GBX 2,500 ($32.67). Morgan Stanley’s target price would indicate a potential downside of 15.00% from the stock’s current price.

A number of other research analysts have also commented on VCT. Citigroup reissued a “neutral” rating on shares of Victrex in a report on Tuesday, July 17th. Barclays reissued an “underweight” rating and set a GBX 2,380 ($31.10) price target (up from GBX 2,300 ($30.05)) on shares of Victrex in a report on Tuesday, July 24th. Liberum Capital reaffirmed a “buy” rating and set a GBX 2,825 ($36.91) target price on shares of Victrex in a research note on Wednesday, July 25th. Peel Hunt reaffirmed an “add” rating on shares of Victrex in a research note on Wednesday, July 25th. Finally, UBS Group reaffirmed a “buy” rating and set a GBX 3,600 ($47.04) target price (up previously from GBX 3,300 ($43.12)) on shares of Victrex in a research note on Thursday, October 4th. Three analysts have rated the stock with a sell rating, six have assigned a hold rating and four have given a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of GBX 2,560.45 ($33.46).

Shares of VCT traded down GBX 14 ($0.18) during trading hours on Friday, reaching GBX 2,706 ($35.36). 183,640 shares of the company’s stock traded hands, compared to its average volume of 274,177. Victrex has a twelve month low of GBX 1,826 ($23.86) and a twelve month high of GBX 2,772 ($36.22).

About Victrex

Victrex plc, through its subsidiaries, manufactures and sells polymers worldwide. It operates through two segments, Victrex Polymer Solutions and Invibio Biomaterial Solutions. The company offers VICTREX PEEK polymer materials; and biomaterial solutions for use in spine, dental, trauma, knee, cardiovascular, and orthopedic applications.

See Also: Preferred Stock

Analyst Recommendations for Victrex (LON:VCT)

Receive News & Ratings for Victrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Victrex and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.